지엘팜텍
Financials
Valuation Metrics
지엘팜텍's Market Cap is ₩631B. At end of 2025 it was ₩846B. Ranked #1577 of 2,436 in KR market (top 65%), #923 of 1,649 on KOSDAQ (top 56%), #175 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 63.12B KRW | KR#1,577/2,436 Sec#175/234 |
| Revenue | 36.86B KRW | KR#1,943/2,436 Sec#134/234 |
| Net Income | -131.6M KRW | KR—/2,436 Sec—/234 |
| Total Assets | 48.60B KRW | KR#2,196/2,436 Sec#199/234 |
| Net Assets | 19.80B KRW | KR#2,283/2,436 Sec#216/234 |
| Employees | 25 | KR#2,200/2,436 Sec#204/234 |
| Value | ||
| P/B | 3.19x | KR#2,136/2,436 Sec#169/234 |
| P/S | 1.71x | KR#1,739/2,436 Sec#98/234 |
| EV/EBITDA | 477.86x | KR#1,554/2,436 Sec#110/234 |
| FCF Yield | -6.85% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -0.66% | KR#1,544/2,436 Sec#106/234 |
| ROA | -0.27% | KR#1,522/2,436 Sec#106/234 |
| Op. Margin | 0.47% | KR#1,550/2,436 Sec#110/234 |
| Revenue Growth | 20.34% | KR#635/2,436 Sec#60/234 |
| Earnings Growth | -598.48% | KR#1,646/2,436 Sec#110/234 |
| Financial Health | ||
| Debt Ratio | 245.49% | KR#1,980/2,436 Sec#211/234 |
| Total Debt | 23.42B KRW | KR#1,300/2,436 Sec#108/234 |
| FCF | -4.33B KRW | KR#1,472/2,436 Sec#115/234 |
| Cash | 3.02B KRW | KR#2,151/2,436 Sec#202/234 |
| Current Ratio | 0.95x | KR#1,871/2,436 Sec#186/234 |
| Performance | ||
| 1Y Return | -34.09% | KR#1,676/2,436 Sec#147/234 |
| 1M Return | -1.21% | KR#1,020/2,436 Sec#98/234 |
| From 52W High | -38.80% | KR#704/2,436 Sec#49/234 |
| 1Y MDD | -38.78% | KR#480/2,436 Sec#37/234 |
| Trading | ||
| Foreign Own. | 1.48% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -2 KRW | KR—/2,436 Sec—/234 |
| BPS | 255 KRW | KR#2,422/2,436 Sec#233/234 |
Company Info
GL Pharm Tech, established in 2014 and headquartered in Seongnam-si, Gyeonggi-do, is a specialized enterprise in pharmaceutical research and development services and sales & marketing, listed on KOSDAQ in 2014. The company focuses on developing incrementally modified drugs using Drug Delivery System (DDS) technologies like controlled release and drug absorption enhancement. Its consolidated subsidiary, GL Pharma Co., Ltd., possesses hormone drug production facilities, which only a few domestic pharmaceutical companies have, and produces and sells pharmaceuticals, expanding its business into contract manufacturing and sales.